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Edited by Lukas HuberAbstract The eﬃciency of small interfering RNA (siRNA)-
induced gene knockdown is hampered by low transfection
eﬃciency. We established a novel and simple double transfection
method using speciﬁc siRNA duplexes targeted against human
thrombin receptor PAR-1 in DU 145 prostate cancer cells. The
initial siRNA transfection of cell suspensions followed by re-
transfection of adherent cells on the following day resulted in
undetectable PAR-1 mRNA and absent receptor protein. PAR-1
mRNA expression was silenced for up to ﬁve days. Functional
studies showed that PAR-1 gene silencing in DU 145 cells
abolished the modulating eﬀects of thrombin on cell adhesion to
the extracellular matrix proteins, ﬁbronectin and laminin, thus
demonstrating the essential role of PAR-1 in mediating thrombin
eﬀects on DU 145 cell adhesion.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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RNA interference (RNAi) is a gene-regulating process in
which double-stranded RNA (dsRNA) intracellularily trig-
gers post-transcriptional suppression of homologous gene
expression. Although the mechanism of RNAi is not yet
understood in full detail, a multi-step process seems to be
involved. A ribonuclease III-related enzyme called Dicer
cleaves long dsRNA into small interfering RNA duplexes
(siRNAs), which participate in the formation of an eﬀector
complex (RNA-induced silencing complex or RISC) target-
ing complementarily homologous mRNA degradation and
gene silencing [1].
Long dsRNA species (>30 bp) usually induce rapid and
global gene knockdown in mammalian cells. Therefore, 21- to
28-nucleotide sequence-speciﬁc siRNAs with 30-overhangs
have been designed for improved speciﬁcity. Induction of
siRNA in mammalian cells can inhibit expression of target* Corresponding author. Fax: +49-391-4947672.
E-mail address: michael.steiner@med.uni-rostock.de (M. Steiner).
Abbreviations: RNAi, RNA interference; siRNA, small interfering
RNA; dsRNA, double-stranded RNA; PAR-1, protease-activated
receptor 1; ECM, extracellular matrix; FN, ﬁbronectin; LN, laminin
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genomics [2]. In addition, systemic delivery of siRNA inhibits
gene expression in murine disease models [3].
Although RNAi techniques have been widely used in gene
functional analysis, siRNA-mediated gene silencing is ham-
pered frequently due to low delivery eﬃcacy of either syn-
thetic siRNAs or vector-based systems to target cells [4]. The
eﬃcacy of RNAi-induced gene silencing depends on cell
type, RNAi target, amount of siRNA and delivery method
with optimal transfection being critical for successful inhi-
bition of gene expression. The identiﬁcation of optimal
transfection conditions usually requires time-consuming and
expensive experiments.
Accumulating evidence indicates that the serine protease
thrombin, in addition to its central role in hemostasis and
thrombosis, is involved in a variety of aspects related to
tumor pathogenesis [5]. The identiﬁcation and molecular
understanding of a subfamily of G protein-coupled recep-
tors, referred to as protease-activated receptors (PARs) of
which PAR-1, -3, and -4 are proteolytically activated by
thrombin, provide mechanistic explanations with respect to
the interplay between malignancy and thrombin [6]. PAR-1
is believed to mediate most if not all of the cellular eﬀects
exerted by thrombin and is expressed by a variety of es-
tablished tumor cell lines and primary tumor tissues [5]. The
role of PAR-1 can be conﬁrmed by receptor activating
peptides. However, molarity of peptides required is several
orders of magnitudes higher than that of thrombin [7–9].
Moreover, the eﬀects of thrombin on several cell types were
not completely mimicked by PAR-1 activating peptides
[10,11].
Expression of the major thrombin receptor PAR-1 was
demonstrated in several widely used prostate cancer cell lines
[9,12,13]. In addition, thrombin modulates Rho signaling
[14], proliferation [13] and secretion of vascular endothelial
growth factor [9] in prostate cancer cells. However, the ex-
clusive contribution of PAR-1 to the eﬀects observed after
thrombin treatment in prostate cancer cells remains to be
shown.
In the present study, we established a novel double trans-
fection method using synthetic siRNA and demonstrated
undetectable expression of PAR-1 for up to ﬁve days after
transfection in DU 145 prostate cancer cells. In addition, the
essential role of PAR-1 for thrombin-induced cell adhesion
to extracellular matrix (ECM) proteins was conclusively
established.blished by Elsevier B.V. All rights reserved.
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2.1. Cell culture
The human prostate cancer cell line DU 145 (ATCC, Manassas, VA,
USA) was maintained in RPMI 1640 medium supplemented with 10%
fetal calf serum (FCS), 2% glutamine, and penicillin/streptomycin
(Biochrom, Berlin, Germany). Subculturing was performed with 0.05%
trypsin/0.02% EDTA. DU 145 cells in passages 25–40 were used for
experiments.
2.2. Transfection with small interfering RNA
Transfection of adherent cells. The speciﬁc siRNA duplexes tar-
geted against human thrombin receptor PAR-1, siRNA transfection
reagent, and reduced-serum transfection medium were purchased
from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The day
before transfection, 4 104 cells were seeded in each well of 12-well
cell culture plates in RPMI 1640 medium containing 10% FCS
without antibiotics and incubated for 24 h. The next day, trans-
fection complexes were prepared using PAR-1 siRNA, siRNA
transfection reagent, and transfection medium according to the
manufacturer’s instructions and were delivered to cell monolayers in
600 ll fresh media with 50 or 100 nM ﬁnal concentration of siRNA
duplexes. A scrambled siRNA (Santa Cruz Biotechnology) was used
as negative control.
Transfection of cell suspensions. A modiﬁed transfection protocol
was used [15] with siRNA transfection complexes prepared as above.
To compensate for cell proliferation from the time of seeding to
transfection in adherent cells, increased cell numbers (8 104) in single
cell suspensions prepared by trypsinization were gently mixed with
transfection complexes containing either 50 or 100 nM ﬁnal concen-
tration of siRNA and plated in 12-well plates in growth media without
antibiotics. Cells were incubated with transfection complexes for 5 h,
followed by replacement of 90% of the transfection media with fresh
growth media without transfection complexes.
Double transfection. DU 145 cells (8 104) were initially transfected
with either 25 or 50 nM of siRNA in suspensions for 5 h before re-
placement of 90% volume of transfection media. After 24 h of incu-
bation, adherent cells were re-transfected with siRNA at the same
concentration as transfection performed in suspension. Thereafter,
50% of media volumes were replaced every 3 days with fresh culture
media.
2.3. RNA isolation and semi-quantitative duplex RT-PCR
Cells cultured in 12-well plates were harvested at diﬀerent time
points as indicated and cellular RNA isolated using 0.5 ml TRIzol
reagent (Life Technologies, Karlsruhe, Germany) for each well of cells
according to the manufacturer’s instructions. Total RNA was digested
with 1 unit RQ1 RNase-free DNase (Promega, Madison, WI, USA)
per lg RNA. 2 lg of total RNA was reverse-transcribed using random
hexamers and the Superscript II preampliﬁcation system (Life Tech-
nologies). Ampliﬁcations were performed in 50 ll reaction mixtures
containing PCR buﬀer (10 mM Tris–HCl, 1.5 mMMgCl2, and 50 mM
KCl, pH 8.3), 0.2 mM of each deoxynucleotide triphosphate, 2 units of
Taq DNA polymerase (Qiagen, Hilden, Germany), 0.2 lM of each
human PAR-1 primer (forward: GTG CTG TTT GTG TCT GTG CT,
reverse: CCT CTG TGG TGG AAG TGT GA) [13], and 40 nM of
each human glyceraldehydes-3-phosphate dehydrogenase (GAPDH)
primer (forward: TCG GAG TCA ACG GAT TTG GTC GTA, re-
verse: AGC CTT CTC CAT GGT GGT GAA GA) [16]. After initial
denaturation (94 C for 5 min), 30 cycles were performed with 1 min
denaturation at 94 C, 1 min annealing at 55 C and 2 min synthesis at
72 C, followed by a 7 min ﬁnal extension step. PCR products were
electrophoresed on 2% agarose gels, stained with ethidium bromide,
and visualized under UV light. The intensity of PCR product was
analyzed by the NIH software ImageJ 1.28u.
2.4. Flow cytometry
After 72 h of siRNA transfection, cells were collected for detection
of PAR-1 expression on the cell surface by ﬂow cytometry analysis
following established procedures [13] with slight modiﬁcations. In
brief, cell monolayers were dissociated by exposure to 50 mM EDTA
and single cell suspensions prepared in PBS containing 2% bovine
serum albumin. Cells were incubated with 50 lg/ml of mouse mono-
clonal anti-human PAR-1 IgG1 (WEDE15, Beckman Coulter Immu-
notech, Krefeld, Germany) at 4 C for 30 min. After washing,phycoerythrin-conjugated goat F ðab0Þ2 anti-mouse IgG was added.
The cells were washed twice and 10 000 cells were analyzed by a
FACScan ﬂow cytometer (Becton Dickinson, Heidelberg, Germany).
Isotypic murine monoclonal antibody (clone MsIgG1) was utilized as
negative control.
2.5. Cell adhesion
DU 145 cells were transfected with siRNA in 12-well plates using the
double transfection protocol. 72 h after the initial transfection, 96-well
culture plates were precoated with 5 lg/cm2 human ﬁbronectin (FN,
Roche, Mannheim, Germany) or 2 lg/cm2 mouse laminin (LN, Roche)
at 37 C for 2 h. Untransfected or transfected cells with either PAR-1
siRNA or control siRNA were harvested with 50 mM of EDTA, re-
suspended in serum-free media containing diﬀerent concentrations of
thrombin and seeded in 96-well plates (2.5 104 cells per well in 100 ll
medium). After 30 min of incubation, media and non-adherent cells
were carefully removed and the plates were washed twice with PBS.
After the addition of 100 ll fresh medium to each well, numbers of
adhesive cells were estimated by incubation with 10 ll WST-1 (Roche)
at 37 C for 30 min and absorbance read at 450 nm as previously
reported [13].
2.6. Statistics
Results are presented as meansS.E.M. Diﬀerences between means
were analyzed by Student’s two tailed t test. Diﬀerences were regarded
statistically signiﬁcant at P 6 0:05.3. Results
3.1. Comparison of gene silencing eﬃcacy of diﬀerent
transfection protocols
Initially, we used a target-speciﬁc siRNA against human
thrombin receptor PAR-1 to transfect adherent DU 145
prostate carcinoma cells by a conventional transfection pro-
tocol. After 48 h of transfection with 50 nM PAR-1 siRNA,
PAR-1 mRNA expression was downregulated to 27% residual
level compared to untreated cells (Fig. 1). The scrambled
control siRNA had no signiﬁcant eﬀect on PAR-1 expression.
Increasing PAR-1 siRNA concentration to 100 nM was un-
successful due to 80% cell detachment 48 h post transfection
(data not shown).
Transfection of DU 145 cell suspensions was attempted. To
minimize the prolonged presence of transfection complexes in
cell suspensions causing cytotoxic eﬀects, 90% volume of me-
dia containing transfection complexes were replaced with fresh
media after 5 h to reduce the concentration of complexes and
to avoid decreasing cell numbers. Transfection of siRNA at 50
nM in cell suspensions improved PAR-1 gene silencing (18%
residual mRNA expression compared to untreated cells),
which was however still incomplete. Transfection of control
siRNA in suspensions did not inhibit expression of PAR-1
mRNA (Fig. 1). siRNA applied at 100 nM displayed pro-
nounced cytotoxic eﬀects in DU 145 suspensions within 5 h
rendering this approach impossible.
Alternatively, we aimed to test a double transfection method
with initial transfection of DU 145 cell suspensions followed
by re-transfection of adherent cells on the following day.
Double transfection with 25 nM siRNA suppressed PAR-1
mRNA expression to 22% residual level 48 h post the initial
transfection, while application of 50 nM siRNA using the
double transfection protocol resulted in undetectable PAR-1
mRNA (Fig. 1). Furthermore, gene silencing was demon-
strated at the protein level by ﬂow cytometry, indicating absent
thrombin receptor PAR-1 on the cell surface 72 h after the
initial transfection (Fig. 2).
Fig. 1. Comparison of gene silencing eﬀects of siRNA on thrombin receptor (PAR-1) expression of DU 145 cells using diﬀerent transfection pro-
tocols. Cells were transfected with either 50 nM ﬁnal concentration of PAR-1 siRNA or negative control siRNA (Cont.) in adherent cells (A50) or in
suspensions (S50), respectively. Cells were also initially transfected in suspensions with either 25 or 50 nM siRNA followed by re-transfection of
adherent cells after 24 h with the same siRNA concentration as used for the ﬁrst transfection (S+A25 and S+A50). Total RNA was extracted 48 h
post-(initial) transfection, RNA was reverse-transcribed and cDNAs ampliﬁed by duplex RT-PCR to determine the expression levels of PAR-1
mRNA. The intensity of PAR-1 signals was normalized to GAPDH expression using the NIH ImageJ software (UT, untreated; UD, undetectable).
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Using the double transfection protocol, PAR-1 transcripts in
DU 145 cells were silenced by RNAi for up to ﬁve days post
the initial transfection (Fig. 3). After seven days, PAR-1
mRNA re-emerges with 27% relative intensity compared to
controls, which is equal to the inhibitory level obtained two
days after transfection using the conventional method (Figs. 1
and 3).
3.3. Abolishment of thrombin-induced cell adhesion by PAR-1
silencing
The presence of thrombin in cell culture media induced cell
adhesion to the ECM components, ﬁbronectin (FN, Fig. 4A)Fig. 2. Flow cytometric analysis of PAR-1 gene knockdown of DU 145
cells by double transfection with 50 nM of siRNA performed in cell
suspensions and adherent cells. Cells were collected 72 h post initial
transfection to detect PAR-1 protein expression on cell surface using
the monoclonal antibody WEDE15 against PAR-1.and laminin (LN, Fig. 4B). The presence of thrombin in con-
centrations ranging from 0.1 to 1.0 U/ml stimulated DU 145
adhesion to FN compared to control cells without thrombin
treatment (0.1 U/ml: P ¼ 0:022; 0.5 U/ml: P ¼ 0:031; and 1.0
U/ml: P ¼ 0:028). DU 145 cell adhesion to LN was also
stimulated by thrombin (0.1 U/ml: P ¼ 0:014; 0.5 U/ml:
P ¼ 0:036; and 1.0 U/ml: P ¼ 0:054). Maximal adhesion of
DU 145 cells to ECM proteins was observed in the presence of
0.5 U/ml thrombin.
DU 145 cells with PAR-1 knockdown were used for adhe-
sion assays 72 h after initial transfection. Lack of PAR-1 in
transfected cells caused cellular unresponsiveness to 0.5 U/ml
thrombin with respect to adhesion to either FN or LN (Fig. 5A
and B), whereas control siRNA did not aﬀect the modulating
eﬀects of thrombin on DU 145 adhesion to ECM proteins.4. Discussion
Since the introduction of speciﬁc suppression of gene ex-
pression in mammalian cells using siRNA [17], RNAi tech-
niques have been widely adopted in functional gene analysis.
Delivery of synthetic siRNA or vector-based siRNA expres-
sion systems to target cells reverses the expression and function
of the gene under consideration.
Similar to other nucleic acid-based approaches, optimal in-
troduction of siRNA into target cells is critical for gene si-
lencing. Complete gene silencing is diﬃcult to achieve with low
delivery rates. Incomplete siRNA-induced gene suppression
may result from the presence of a fraction of mRNA in a
protected compartment such as spliceosomes, other nuclear
locations or non-transfected cells [18]. Improved RNAi-
mediated gene silencing has been reported using several ap-
proaches, including the application of multiplex siRNAs
against the same gene [19], conjugation of siRNA with mem-
brane permeant peptides [20], and introduction of mismatches
Fig. 3. Kinetics of gene silencing after double transfection of PAR-1 siRNA in DU 145 cells. Total cellular RNA was isolated at diﬀerent time points
and relative RT-PCR performed to examine PAR-1 mRNA levels (UT, untreated; UD, undetectable).
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Fig. 4. Thrombin-induced modulation of DU 145 cell adhesion to
extracellular matrix components. Cells suspended in serum-free media
with diﬀerent concentrations of thrombin were seeded into plates
precoated with either ﬁbronectin (FN, 5 lg/cm2, A) or laminin (LN, 2
lg/cm2, B). After 30 min of incubation, unbound cells were removed
and adhesive cells assayed by WST-1 reagent. Data were obtained
from four independent experiments.
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tory adherent cells was achieved by transfection of cell
suspensions instead of attached cells [15].In the present study, we utilized a single siRNA corre-
sponding to the thrombin receptor PAR-1 in prostate carci-
noma DU 145 cells using a double transfection method with
initial transfection of cell suspensions for 5 h and re-transfec-
tion of adherent cells on the following day. PAR-1 mRNA was
undetectable 48 h after the initial transfection and PAR-1
knockdown was conﬁrmed at the protein level by ﬂow cy-
tometry. In contrast, transfection with PAR-1 siRNA of ad-
herent DU 145 cells using a standard protocol inhibited
only approximately 70% of PAR-1 expression and a single
transfection of cell suspensions caused approximately 80%
inhibition.
Using the double transfection protocol, highly eﬃcient
PAR-1 gene silencing was achieved with four additionally
designed siRNA duplexes directed against diﬀerent PAR-1
target sites, one of which totally abolished PAR-1 mRNA
expression in DU 145 cells 48 h after transfection (data not
shown). However, the general applicability of the double
transfection approach remains to be demonstrated with respect
to additional genes and other adhesive cell types.
It was suggested that trypsinization-induced cell surface
availability to transfection complexes or cellular changes
during cell attachment/detachment to or from culture plates
may modulate uptake of siRNA [15]. Although the kinetics of
siRNA uptake in DU 145 cells has not been studied, it should
be noted that siRNA delivery to keratinocytic cells reached
maximal level after transfection for 2–4 h [18]. In our studies,
the deprivation of siRNA-containing media 5 h post trans-
fection to minimize cytotoxic eﬀects for adherent cells kept in
suspension presumably resulted in a subpopulation of non-
transfected cells and incomplete PAR-1 silencing. After over-
night cellular attachment to cell culture plates, adherent DU
145 cells were subject to a second siRNA transfection to de-
liver additional siRNA to both transfected and non-trans-
fected cells, which resulted in complete PAR-1 gene
knockdown. Another possible mechanism involved is delayed
recovery of mRNA levels by repeated exogenous applications
of synthetic siRNA [22].
Synthetic siRNA-induced gene silencing in proliferating
mammalian cell cultures is transient by its nature. However,
the persistence of gene silencing is a critical parameter to
perform experiments in gene-silenced cells. It was previously
reported that the expression of targeted genes recovered to
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Fig. 5. PAR-1 silencing by RNAi using double transfection abolishes
thrombin-induced DU 145 cell adhesion to extracellular matrix com-
ponents. 72 h post the initial transfection of siRNA, untreated or
transfected cells with control or PAR-1 siRNA were harvested in se-
rum-free media and cell adhesion assayed with or without 0.5 U/ml
thrombin for 30 min. Cell adhesion to extracellular matrix proteins,
ﬁbronectin (FN, A) and laminin (LN, B), was assayed. (UT, untreated;
Thr, thrombin; w/o, without).
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[18,23]. Our data demonstrated undetectable PAR-1 mRNA in
doubly transfected DU 145 cells up to 5 days after the initial
transfection. After 7 days, PAR-1 mRNA re-emerged at a level
comparable to that obtained 48 h after conventional trans-
fection, thus indicating more eﬀective gene silencing by double
transfection compared to standard protocols. It seems rea-
sonable to suggest that the modiﬁed transfection method in-
duces longer persistence of reduced PAR-1 before expression
returns to the normal level.
Although no attempts have been undertaken to speciﬁcally
address the question if non-speciﬁc changes are induced in
genes other than the target, it should be noted that the double
transfection protocol using siRNA at 50 nM concentration
improves PAR-1 silencing without causing signiﬁcant cyto-
toxic eﬀects for at least 7 days after transfection, thus ex-
cluding oﬀ-target gene modulation associated with major
cytotoxicity or cell death [2].Adhesion of tumor cells to platelets, vascular endothelium
and ECM modulates their invasive and metastatic capacity.
Thrombin has been reported to activate tumor cells to express
various adhesion molecules and stimulate cellular adhesion to
endothelial cells, platelets and ECM components [24]. PAR-1
activation peptide can mimic thrombin-induced adhesion,
suggesting that the eﬀect of thrombin is mediated by proteo-
lytic activation of PAR-1 [8,25]. In addition, thrombin en-
hanced adhesion of B16F10 melanoma cells transfected with
full-length PAR-1 sense cDNA to ﬁbronectin compared to
mock-transfected cells, demonstrating the importance of PAR-
1 in thrombin-induced cell adhesion [26]. Results from the
present study indicate that the presence of thrombin for 30 min
stimulated prostate cancer cell adhesion to ECM proteins, ﬁ-
bronectin and laminin. This eﬀect seems to be exclusively de-
pendent on the presence of the thrombin receptor PAR-1, since
PAR-1 silencing by RNAi completely abolished thrombin’s
eﬀects on cell adhesion.
In conclusion, our data demonstrate that the novel double
transfection method eﬀectively improves gene silencing of
thrombin receptor PAR-1 in DU 145 prostate cancer cell line.
The absence of PAR-1 abolishes thrombin-modulated cell
adhesion to ECM proteins, thus conclusively establishing the
role of PAR-1 in mediating thrombin’s eﬀect. Highly eﬃcient
RNAi-induced gene silencing of PAR-1 provides a novel tool
to characterize the complex interaction between thrombin and
its receptor in prostate tumor biology. Compared with rather
complex attempts to enhance eﬀective inhibition of endoge-
nous gene expression by RNAi especially in adhesive cells, the
present study provides a simple alternative by applying a
double transfection strategy. Further studies should be per-
formed to evaluate the approach with respect to other cell
types and genes under consideration.
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